The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

With a nickname, logos and everything that goes with a permanent brand identity now officially a part of who they are, the ...

The Winnipeg Jets host the Dallas Stars in Game 2 of their second round Stanley Cup Playoffs series on Friday, May 9.

They unveiled Utah Mammoth as the franchise’s permanent, full-time name Wednesday, with a profiled logo of the ice age ...

Compass Pathways PLC (CMPS) advances in treatment-resistant depression trials while maintaining a robust financial position.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Phase 3 results Tarlatamab (Amgen) Bispecific delta-like ligand 3-directed CD3 T-cell engager Treatment of small cell lung cancer in patients who progressed on or after a single line of platinum ...

SolarEdge's new solar-powered EV charger helps businesses cut fleet charging costs by up to 70%, and it's available now.

Ooops... Something went wrong while loading this page.